KOPS - Das Institutionelle Repositorium der Universität Konstanz

Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?

Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?

Zitieren

Dateien zu dieser Ressource

Prüfsumme: MD5:0e037f10b984df7d27f500f71056bd2a

KRÄMER, Julia, Jan-Gerd TENBERGE, Ingo KLEITER, Wolfgang GAISSMAIER, Tobias RUCK, Christoph HEESEN, Sven G. MEUTH, 2017. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?. In: PLOS ONE. 12(4), e0174858. eISSN 1932-6203

@article{Kramer2017progr-39148, title={Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?}, year={2017}, doi={10.1371/journal.pone.0174858}, number={4}, volume={12}, journal={PLOS ONE}, author={Krämer, Julia and Tenberge, Jan-Gerd and Kleiter, Ingo and Gaissmaier, Wolfgang and Ruck, Tobias and Heesen, Christoph and Meuth, Sven G.}, note={Article Number: e0174858} }

<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/39148"> <dc:contributor>Kleiter, Ingo</dc:contributor> <dc:creator>Tenberge, Jan-Gerd</dc:creator> <dc:language>eng</dc:language> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/39148"/> <dc:creator>Kleiter, Ingo</dc:creator> <dcterms:title>Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?</dcterms:title> <dc:contributor>Meuth, Sven G.</dc:contributor> <dcterms:abstract xml:lang="eng">Progressive multifocal leukoencephalopathy (PML) is one of the major risks of natalizumab therapy. Despite introduction of the currently employed PML risk stratification algorithm, the incidence of natalizumab-associated PML cases is not decreasing.</dcterms:abstract> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-06-07T09:26:48Z</dcterms:available> <dcterms:issued>2017</dcterms:issued> <dc:contributor>Tenberge, Jan-Gerd</dc:contributor> <dcterms:rights rdf:resource="http://nbn-resolving.de/urn:nbn:de:bsz:352-20150914100631302-4485392-8"/> <dc:contributor>Gaissmaier, Wolfgang</dc:contributor> <dc:creator>Ruck, Tobias</dc:creator> <dc:creator>Gaissmaier, Wolfgang</dc:creator> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-06-07T09:26:48Z</dc:date> <dc:creator>Krämer, Julia</dc:creator> <dc:contributor>Ruck, Tobias</dc:contributor> <dc:contributor>Krämer, Julia</dc:contributor> <dc:creator>Meuth, Sven G.</dc:creator> <dc:creator>Heesen, Christoph</dc:creator> <dc:contributor>Heesen, Christoph</dc:contributor> </rdf:Description> </rdf:RDF>

Dateiabrufe seit 07.06.2017 (Informationen über die Zugriffsstatistik)

Kraemer_0-408546.pdf 21

Das Dokument erscheint in:

KOPS Suche


Stöbern

Mein Benutzerkonto